— Know what they know.
Not Investment Advice
Also trades as: FME.DE (XETRA) · $vol 44M · FME.SW (SIX) · $vol 0M · FMCQF (OTC) · $vol 0M

FMS NYSE

Fresenius Medical Care AG & Co. KGaA
1W: +0.3% 1M: +6.5% 3M: +9.5% YTD: +5.3% 1Y: -6.3% 3Y: -4.8% 5Y: -33.1%
$24.75
-0.12 (-0.48%)
 
Weekly Expected Move ±3.1%
$23 $24 $25 $25 $26
NYSE · Healthcare · Medical - Care Facilities · Alpha Radar Buy · Power 66 · $13.3B mcap · 490M float · 0.152% daily turnover · Short 59% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$13.3B
52W Range20.02-27.64
Volume1,183,746
Avg Volume746,867
Beta0.82
Dividend$0.86
Analyst Ratings
5 Buy 13 Hold 2 Sell
Consensus Hold
Company Info
CEOHelen Giza
Employees108,165
SectorHealthcare
IndustryMedical - Care Facilities
IPO Date1996-09-17
Else-KrOener Strasse 1
Bad Homburg, HE 61352
DE
49 6172 608 2522
About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.

Recent Insider Trades

NameTypeSharesPriceDate
Renkewitsch Olga 0 2026-03-18

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms